ALS Association, I AM ALS Call on FDA, Amylyx to Make AMX0035 Available to People With ALS
September 04, 2020
September 04, 2020
WASHINGTON, Sept. 4 -- The Amyotrophic Lateral Sclerosis Association issued the following news release on Sept. 2:
Today, in response to the New England Journal of Medicine publication of encouraging clinical trial results showing that Amylyx Pharmaceuticals' AMX0035 brought statistically significant benefit to people living with ALS, The ALS Association and I AM ALS immediately called on the drug company and the FDA to make the treatment widely available as soon as possible. D . . .
Today, in response to the New England Journal of Medicine publication of encouraging clinical trial results showing that Amylyx Pharmaceuticals' AMX0035 brought statistically significant benefit to people living with ALS, The ALS Association and I AM ALS immediately called on the drug company and the FDA to make the treatment widely available as soon as possible. D . . .